Company Overview of Vaxil Bio Ltd.
Vaxil Bio Ltd., a clinical stage biotechnology company, engages in the development of novel, immunotherapeutic products, peptides, and antibodies for the treatment of cancer and infectious diseases in Israel. The company’s lead product is ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen that completed Phase II clinical trials; and is in Phase I/II clinical trials for the treatment of metastatic breast cancer patients in combination with hormonal therapy. It also develops MTbuVax, a multi-antigenic and multi-epitope subunit vaccine, which is in preclinical stage to treat intracellular pathogenic bacteria mycobacterium tuberculosis; and SPmAb, an antibody for the di...
4576 Yonge Street
Founded in 2006
Key Executives for Vaxil Bio Ltd.
President and Chief Financial Officer
Total Annual Compensation: 726.0K
Total Annual Compensation: 848.0K
Compensation as of Fiscal Year 2014.
Vaxil Bio Ltd. Key Developments
Vaxil Bio Ltd. Announces Executive Changes
Oct 20 16
Vaxil Bio Ltd. announced a collaboration with Hadassah Medical Center. In addition to the Vaxil-Hadassah Collaboration, Hadassah scientist Professor Michael Shapira will be joining the Vaxil Scientific Advisory Board. Furthermore, Vaxil is pleased to announced the appointment of Mr. Gadi Levin as interim CEO and as a Director of the Board. Mr. Levin has a strong financial background combined with a successful track record in the biotech field. Previously, Mr. Levin was the Chief Financial Officer of Labstyle Innovations Ltd. Dr. Benjamin Chen has resigned as CEO effective immediately. Dr. Chen will remain on the Vaxil Board of Directors where his focus will primarily pertain to scientific and strategic guidance.
Vaxil Bio Ltd. Announces Management Changes
Feb 29 16
Vaxil Bio Ltd. (formerly Emerge Resources Corp.) announced the closing of its reverse takeover acquisition of Vaxil Bio Ltd., following approval of the transaction and related matters by the shareholders of each of the company and Vaxil Israel. Following closing of the transaction, the company will principally conduct the biotech business of Vaxil Israel, and the board and management of the company will be as follows: Dr. Saeid Babaei - Director and Chairman, Dr. Lior Carmon - Director, Dr. Benjamin Chen - Director and CEO, Dr. Marian Gorecki - Director, Mr. Gadi Levin - CFO and Mr. Isaac Maresky - Executive Director.
Vaxil Bio Ltd., Annual General Meeting, Feb 24, 2016
Feb 10 16
Vaxil Bio Ltd., Annual General Meeting, Feb 24, 2016, at 15:00 Israel Standard Time.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|